PEG-Interferon Alpha Stabilization with Raffinose Cryoprotectant
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of PEG-interferon alpha 2b are unstable in liquid form and require long lyophilization cycles, leading to increased manufacturing costs and higher moisture content, necessitating the development of novel lyophilized and stabilized formulations that are cost-effective and easy to handle.
Innovation Solution
Formulating PEG-interferon alpha conjugates with suitable buffers, cryoprotectants, stabilizers, and solvents, such as trehalose, sodium phosphate, and polysorbate 80, followed by lyophilization, which reduces the lyophilization cycle time and enhances stability and physical strength of the formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If PEG-interferon alpha 2b is formulated in liquid form, then it is easy to administer, but it is unstable and requires frequent administration
Solution Approach 1:
The patent applies freeze-drying (lyophilization) to transition the formulation from liquid to solid frozen state, then to dry powder form. This phase transition enables long-term storage stability while maintaining ease of administration through simple reconstitution with sterile water before injection
Solution Approach 2:
The patent uses cryoprotectants (sucrose, trehalose, raffinose) and stabilizers (polysorbate 80, albumin) as intermediary substances that protect the PEG-interferon alpha conjugate during freezing and storage, enabling both stability in frozen form and ease of reconstitution for administration
2Reliability
If conventional lyophilization is used for PEG-interferon alpha 2b, then stability is improved, but the lyophilization cycle time is excessively long
Solution Approach 1:
The patent modifies lyophilization parameters including using optimized freezing temperatures, adjusted drying rates, and modified pressure conditions to reduce cycle time while maintaining stability. The formulation composition is also adjusted to enable faster drying kinetics
Solution Approach 2:
The patent applies preliminary freezing and pre-drying steps that prepare the formulation for faster subsequent drying. The cryoprotectants are added beforehand to prevent denaturation during the accelerated lyophilization process, enabling reduced cycle time without compromising stability
3Reliability
If conventional lyophilization is used for PEG-interferon alpha 2b, then stability is improved, but manufacturing costs increase
Solution Approach 1:
The patent optimizes lyophilization parameters to reduce energy consumption and processing time, directly lowering manufacturing costs. The formulation is designed to achieve stability at lower drying temperatures and shorter times compared to conventional approaches
Solution Approach 2:
The patent incorporates stabilizers and cryoprotectants in the formulation before lyophilization, which prevents degradation and eliminates the need for expensive post-processing stabilization steps or additional packaging requirements, thereby reducing overall manufacturing costs while maintaining stability
4Reliability
If conventional lyophilization is used for PEG-interferon alpha 2b, then stability is improved, but moisture content in the final product is high
Solution Approach 1:
The patent adjusts drying temperature, pressure, and time parameters to achieve thorough moisture removal while preventing product degradation. The optimized cycle ensures low residual moisture content that enhances long-term storage stability
Solution Approach 2:
The patent adds cryoprotectants and stabilizers before lyophilization that protect the formulation during the extended drying process required to achieve low moisture content, enabling thorough drying without compromising product integrity or stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel formulations provide operational simplicity, improved stability, and reduced manufacturing costs by shortening lyophilization cycles, while maintaining the biologic activity and stability of PEG-interferon alpha conjugates for extended storage.
Implementation Method 1
compositions comprising a peg- interferon alpha conjugate and raffinose as cryoprotectant
Implementation Method 2
lyophilized formulations of PEG-interferon alpha conjugates
Data Source
AI summary
The present invention relates to novel lyophilized and stabilized formulations of PEG-interferon alpha conjugates and the process for their preparation. The novel formulations of PEG-interferon alpha conjugates reported by the inventors of this application require shorter lyophilization cycle and are more cost competitive.